Liquidia (LQDA)

Executive Summary

Liquidia Corporation is a biotechnology company focused on developing and commercializing novel therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's lead product, Yutrepia (treprostinil) inhalation powder, utilizes its proprietary PRINT technology to enable targeted delivery and improved tolerability. Yutrepia is approved for PAH and is under regulatory review for PH-ILD, representing a significant market opportunity. Liquidia also has a robust pipeline of product candidates leveraging its nanoparticle platform. With a recent FDA approval and a growing commercial presence, Liquidia is poised for revenue growth and potential expansion into additional indications. The company's strong intellectual property portfolio and strategic collaborations further bolster its competitive position in the cardiopulmonary space.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on Yutrepia for PH-ILD65% success
• Q4 2026Phase 3 trial data for L606 (liposomal treprostinil) in PAH50% success
• Q2 2026Resolution of patent litigation with United Therapeutics40% success